Guidelines for Authors in Preparing Abstracts
Content & Formatting
• Include a sentence in your abstract stating the study’s objective (unless given in the title); a brief statement of methods, if pertinent; a summary of the results obtained; and a statement of conclusions. It is not acceptable to state, “the results will be discussed.”
• Use a short, specific title.
• Use standard abbreviations for units of measure; other abbreviations should be spelled out in full at first mention, followed by the abbreviation in parentheses (exceptions: RNA, DNA, etc.).
• Do NOT include tables, charts or other figures.
• Be sure to proofread your work carefully before submitting.
Four Ways to Improve Abstract Acceptance
1. Make Certain Your Abstract Includes Results
• Whether new findings presented in an abstract are experimental or theoretical, specific results MUST be included.
• The results, whether experimental or calculated, must be stated in the abstract. An author is free to include her or his latest data in the final poster presented at the meeting, but the results included in the original abstract must be substantive.
2. Avoid Promotion of a Commercial Product or Service
The Abstract Program Committee tries to ensure that CGMOM poster sessions are not used as venues for commercial promotion. Statements like “We show that X product works better than Y product” are clear indicators of promotion, and will be cause for rejection. In contrast, an abstract that presents methods or findings of interest to stem cell researchers, but mentions that the work was done with a proprietary and copyrighted product and co-authors include those at the company that made the product, may be acceptable.
3. Avoid Presentation of Work Already Published Completely Elsewhere
4. Follow the ISSCR Established Guidelines
The Cell & Gene Meeting on the Mesa follows the ISSCR in requiring that researchers presenting results of stem cell therapy or reporting effects of stem cell use in humans must comply with ISSCR’s recommendation for those types of submissions. Abstract submissions must be accompanied by evidence that:
• Work was performed with cells intended for clinical use (i.e., human cells for allogeneic or autologous transplantation; porcine or other for xeno transplantation into humans)
• Preclinical proof of concept data exists demonstrating biological effect on disease/injury target OR: Clinical data exists demonstrating safety and/or efficacy of cells